APRIL is a compact, self-protein that binds 2 MM antigens (BCMA and TACI) with high affinity; we present an APRIL-based CAR.
Dual-antigen targeting increases the availability of tumor-binding sites and reduces the risk of antigen-negative disease escape.
B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM), but expression is variable, and early reports of BCMA targeting chimeric antigen receptors (CARs) suggest antigen downregulation at relapse. Dual-antigen targeting increases targetable tumor antigens and reduces the risk of antigen-negative disease escape. “A proliferation-inducing ligand” (APRIL) is a natural high-affinity ligand for BCMA and transmembrane activator and calcium-modulator and cyclophilin ligand (TACI). We quantified surface tumor expression of BCMA and TACI on primary MM cells (n = 50). All cases tested expressed BCMA, and 39 (78%) of them also expressed TACI. We engineered a third-generation APRIL-based CAR (ACAR), which killed targets expressing either BCMA or TACI (P < .01 and P < .05, respectively, cf. control, effector-to-target [E:T] ratio 16:1). We confirmed cytolysis at antigen levels similar to those on primary MM, at low E:T ratios (56.2% ± 3.9% killing of MM.1s at 48 h, E:T ratio 1:32; P < .01) and of primary MM cells (72.9% ± 12.2% killing at 3 days, E:T ratio 1:1; P < .05, n = 5). Demonstrating tumor control in the absence of BCMA, we maintained cytolysis of primary tumor expressing both BCMA and TACI in the presence of a BCMA-targeting antibody. Furthermore, using an intramedullary myeloma model, ACAR T cells caused regression of an established tumor within 2 days. Finally, in an in vivo model of tumor escape, there was complete ACAR-mediated tumor clearance of BCMA+TACI− and BCMA−TACI+ cells, and a single-chain variable fragment CAR targeting BCMA alone resulted in outgrowth of a BCMA-negative tumor. These results support the clinical potential of this approach.
Multiple myeloma (MM) is a cancer of plasma cells (PC) that is responsible for 2% of cancer deaths.1 Myeloma remains largely incurable, despite significant progress seen with the inclusion of proteasome inhibitors and immunomodulatory drugs into the mainstay of treatment regimens.2 Furthermore, current therapeutic strategies fail to benefit approximately 15% of patients who have primary refractory disease, adverse genetics, or both.3 There remains a need for new myeloma therapies with different mechanisms of action, particularly those that can induce durable remissions.
Chimeric antigen receptors (CAR) typically graft the specificity of a monoclonal antibody (mAb) onto a T cell, redirecting T-cell cytotoxicity to tumor by a mechanism unimpeded by major histocompatibility complex class restriction.4 CAR T cells may have advantages over mAb-based approaches because CAR T cells can actively migrate to sites of disease and persist, thus engendering a sustained rejection of target cells. CD19-directed CAR T-cell therapy has been effective against refractory B-cell malignancies, and sustained responses are seen in the face of chemotherapy-resistant disease.5-9 Applying CAR T-cell therapy to MM, however, faces several challenges, not least of which is target antigen selection. CD19 is expressed in only a small proportion of tumor cells,10 and well-characterized antigens expressed by myeloma such as CD38,11,12 CD56,13,14 and CD13815 may not be suitable targets because of expression outside the lymphoid compartment.
B-cell maturation antigen (BCMA) is a member of the tumor necrosis factor (TNF) receptor superfamily, is upregulated at the terminal stages of B-cell maturation, and is selectively expressed on PC.16,17 BCMA is absent on haemopoietic stem cells16-18 and is expressed by nearly all cases of MM, albeit at variable, and often low, density.16 Consequently, BCMA has been targeted by several immunotherapeutic strategies in MM, including CAR approaches and bispecific T-cell engager therapies.17,19-23 In the first reported clinical trial investigating a BCMA targeting CAR, rapid and dose-dependent disease response was seen in 4 of 12 patients despite substantial tumor load and heavy pretreatment.24 However, relatively high T-cell doses were needed to achieve durable remissions, and possibly akin to CD19 downregulation in CD19 CAR T-cell studies,25 loss of BCMA expression at relapse was reported.24
Thus, although BCMA is a promising target, the challenges of low-target density and target escape may compromise clinical efficacy. To address this, we hypothesized that dual-antigen binding would increase the level of targetable antigen on tumor cells, while potentially reducing the incidence of antigen-negative escape, in this way enhancing therapeutic potential and capacity for long-term disease control. The transmembrane activator and calcium-modulator and cyclophilin ligand (TACI) is also a TNF receptor and is involved in maturation of B cells, including their maturation to PC.26,27 Importantly, TACI is also expressed on MM cells.18,28,29 A proliferation-inducing ligand (APRIL) is a natural ligand of both BCMA and TACI and is an attractive antigen binder because it is a compact, oligomerizing, single-domain self-protein that binds both MM antigens with high, nanomolar affinity.30,31
In this work, we describe a novel CAR construct using a truncated form of APRIL as the tumor-targeting domain (APRIL-based chimeric antigen receptors; ACAR), which recognizes both BCMA and TACI on MM cells. We establish ACAR potency at antigen levels seen in clinical samples, at low effector-to-target ratios (E:T), against primary cells, as well as in murine models of myeloma and tumor escape.
Mononuclear cells (MNCs) were stained with CD138 allophycocyanin (APC) (clone MI15) to identify tumor and murine immunoglobulin G2a (IgG2a) phycoerythrin (PE) isotype control, rat IgG2a PE isotype control, anti-BCMA PE (clone 19F2), or anti-TACI PE (clone 1A1) (all antibodies from BioLegend). BD Fortessa was used for cell acquisition, and data were analyzed using FlowJo_V10 (Treestar). Antibodies bound per cell (ABC) was calculated using BD QuantiBRITE beads and subtracting ABC of isotype control (>100 ABC was considered positive).
All plasmids were cloned in-house32 into the oncoretroviral vector SFG,33 and RD114-pseudotyped supernatant was produced as has been previously described.32 Sequence coding for residues 116 to 250 of the canonical sequence for APRIL (Uniprot 075888) was cloned between signal peptide from IgG κ chain V-III to CAR scaffolds comprising IgG1 hinge spacer, CD8 α spacer, or IgG1 Fc domain34 coexpressed with RQR8 using an in-frame foot-and-mouth–like 2A peptide, TaV.35 Epidermal growth factor receptor vIII (EGFRvIII) and BCMA targeting CARs were engineered using MR1-136 or 11-D-5-317 single-chain variable fragments (scFvs), respectively, a CD8 spacer, and a CD28-OX40-CD3ζ endodomain.
CAR T cells
Peripheral blood mononuclear cells (PBMC) obtained by density gradient centrifugation (Ficoll Paque, GE Lifesciences) were stimulated with CD3 and CD28 antibodies (0.5 µg/mL; Miltenyl) and interleukin-2 (100 IU/mL; Genescript) then transduced as before32 to obtain CAR T cells. Transduction efficiency was assessed by fluorescence-activated cell sorter (FACS) of cells stained for RQR8 (Qbend10 antibody; R&D) or APRIL (anti-APRIL biotin) and RQR8 for ACAR T cells.
Further methods are available in the supplemental Data, available on the Blood Web site.
Primary myeloma cells express BCMA and TACI
We have previously reported the variable surface expression of BCMA on tumor.16 Here, we sought to quantify expression levels of both BCMA and TACI on the cell surface of primary bone marrow (BM)–derived MM cells.
Ficolled BM MNCs from 50 patients were stained for CD138 to identify tumor and anti-BCMA or TACI (Figure 1A; supplemental Table 1, supplemental Figure 1A) by using QuantiBRITE beads for antigen quantification. We found expression of BCMA on CD138+ tumor cells from all patients tested (median: 1061; range: 105-8323 ABC) (Figure 1B). TACI was coexpressed on the tumor (supplemental Figure 1B) and detected on MM cells from 39 of these patients, at generally lower levels (median: 333; range: 0-21 301 ABC) (Figure 1C). Thus, we calculated that concurrent targeting of both antigens in comparison with BCMA alone would increase levels of target antigen in 78% of patients and result in an increased mean combined targetable antigen density on the tumor of 2458 ABC in comparison with 1623. TACI expression also exceeded BCMA in a subset of samples (16%) (supplemental Figure 1C). Notably, 7 of these 8 patients expressed less than the median level of BCMA, suggesting that concurrent TACI targeting may be particularly beneficial in a proportion of BCMAlo tumors.
In keeping with our previous findings,16 patients with a new diagnosis of myeloma (54%) expressed lower levels of BCMA (P < .05) than did those with relapsed disease (46%), but there was no such correlation with TACI expression (P = .3; supplemental Figure 1D). Of the 42 (84%) patients for whom fluorescence in situ hybridization was available, the 25 (60%) patients with high-risk cytogenetic lesions had higher levels of BCMA (P < .05 by Mann-Whitney) but a trend to lower levels of TACI (P = .06) (supplemental Figure 1E).
Thus we confirm the surface tumor expression of BCMA on tumors from all patients tested and the coexpression of BCMA and TACI in the majority (78%) of patients, supporting a therapeutic strategy for myeloma that targets both of these antigens.
Similar expression pattern of BCMA and TACI in normal tissues
The selectivity of BCMA expression to lymphoid cells17 and more specifically PC has been previously described.16 TACI is also a known lymphoid antigen expressed mainly on B cells, but at an earlier stage of maturation and particularly in maturing subsets of splenic B cells.37 Because expression of TACI on normal tissues is less well known, we performed reverse transcription-polymerase chain reaction (qRT-PCR) of BCMA and TACI in a range of normal tissues.
Transcript analysis from 72 normal tissues, each from 3 donors, revealed the highest levels of BCMA and TACI expression in lymphoid tissues. Notable expression levels were also seen in gastrointestinal and bronchial tissues, which likely reflects the presence of lymphocytes at these anatomical sites. BCMA, but not TACI, expression was also noted in testes and gall bladder (supplemental Figure 2, supplemental Table 2). BCMA and TACI transcripts were equally high in the splenic parenchyma, but it is noteworthy that in other tissues, BCMA gene expression was up to 10-fold higher than was TACI.
These data are consistent with TACI expression being restricted to the lymphoid compartment, with distribution broadly similar to that of BCMA.
Optimization of APRIL-based CAR constructs
APRIL is a soluble ligand that binds BCMA and TACI. Additionally, the amino terminus of APRIL binds proteoglycans 38,39 but is not involved in the interaction with BCMA or TACI. To confirm that a truncated form of APRIL could bind BCMA and TACI when expressed on a cell surface, we fused truncated APRIL to the CD8 transmembrane domain and expressed this on SUPT1 cells. Staining with recombinant soluble BCMA and TACI confirmed that truncated APRIL is both stably expressed and maintains BCMA and TACI binding when membrane bound (supplemental Figure 3A). Furthermore, surface plasmon resonance analysis of soluble, truncated APRIL binding to TACI and BCMA confirmed previously described binding kinetics (supplemental Figure 3B).40
Next, 3 ACARs were constructed, consisting of truncated APRIL fused to a spacer domain, a CD28 transmembrane, and tripartite endodomain (CD28-OX40-CD3ζ).41 Spacers were either the hinge of human IgG1 (ACAR-H), the stalk of human CD8α (ACAR-CD8), or the hinge, CH2, and CH3 domains of human IgG1 modified to reduce Fc receptor binding42 (ACAR-Fc) (Figure 2A).
PBMCs from normal donors were activated with IL-2, anti-CD28, and CD3 antibodies, retrovirally transduced with ACAR constructs, CD56 depleted, and tested against SUPT1 cells modified to express high levels of BCMA, TACI, or nontransduced (NT) targets. Using 4-hour 51Cr release assay, T cells transduced with ACAR-H (n = 5), and ACAR-CD8 (n = 6) spacer variants caused cytolysis of SUPT1BCMA (P < .01 for both ACAR constructs in comparison with PBMC NT at an E:T ratio of 16:1, paired t test) and SUPT1TACI (P < .05 for both ACAR constructs) targets. In comparison, ACAR-Fc–transduced T cells killed SUPT1BCMA targets (n = 3, P < .05) but not TACI-expressing targets (Figure 2B).
After coculture with antigen-expressing target cells (1:1 with irradiated, SUPT1 cells) for 24 hours, interferon γ (IFNG) release from ACAR-H (n = 5) and ACAR-CD8 (n = 6) T cells was detected. There was significant cytokine release observed on coculture of both of these ACAR constructs with SUPT1BCMA (P < .01 for both) and SUPT1TACI (P < .05 for both) in comparison with control targets. In comparison, ACAR-Fc did not result in cytokine release against TACI- or BCMA-expressing SUPT1 cells (n = 3) (Figure 2C).
To assess proliferation of ACAR T cells, we stained effector T cells with Cell Trace Violet prior to 1:1 coculture with SUPT1 targets and analyzed them by FACS at 4 days. In comparison with control cocultures with SUPT1NT targets, there was a significant increase in the percentage of proliferated ACAR-H–transduced and ACAR-CD8–transduced T cells with SUPT1BCMA and SUPT1TACI (P < .001 for both effectors with BCMA- and TACI-expressing targets) (Figure 2D; supplemental Figure 4).
Taken together, these data indicate that both ACAR-CD8 and ACAR-H demonstrated greater in vitro activity, compared with ACAR-Fc–transduced T cells. Both spacer variants resulted in target cytolysis, cytokine release, and effector proliferation in response to SUPT1BCMA or SUPT1TACI.
APRIL CAR causes target cytolysis at low antigen densities, at a low E:T ratio, and in the presence of soluble APRIL, BCMA, and TACI
Clinical responses will likely require ACAR activity against the low levels of BCMA and TACI found on some primary MM cells, and at low E:T ratios. We thus explored the in vitro cytolytic potential of the 2 most promising ACAR constructs (ACAR-H and ACAR-CD8) under these conditions.
ACAR-transduced PBMCs were tested against SUPT1 targets expressing a wide range of surface BCMA (421 to 1.5 × 105 ABC) and TACI (1063 to 6.3 × 104 ABC) (Figure 3A). By 51Cr release, T cells transduced with either ACAR construct caused significant cytolysis of all BCMA- and TACI-expressing targets in comparison with control at all E:T ratios tested (32:1 to 4:1, 16:1, shown in supplemental Figure 5A). In an attempt to more closely replicate physiological conditions, cocultures were then extended to 48 hours and the E:T ratio lowered to 1:10 and target kill assessed by FACS. In these conditions, T cells transduced with ACAR-H and ACAR-CD8 both caused significant target cytolysis of unirradiated targets expressing even the lowest levels of BCMA and TACI (Figure 3B).
ACAR-mediated cytolysis of MM cells was confirmed in a number of human myeloma cell lines (HMCLs; supplemental Figure 5B). ACAR activity was also demonstrated at lower E:T ratios against MM.1s and U266 HMCL with significant target cytolysis down to an E:T ratio of 1:32 on coculture with T cells transduced with both ACAR constructs (Figure 3C). T cells transduced with a BCMA-targeting CAR (BCMA CAR) based on the 11-D-5-317,24 scFv were also compared with the ACAR, and despite low E:T ratios, there was no statistically significant difference in kill of MM.1s or U266 by the BCMA CAR and ACAR (supplemental Figure 5C).
Members of the TNF receptor superfamily found in the sera of MM patients may interfere with an APRIL-based therapeutic strategy by blockade or inadvertent T-cell activation. We therefore quantified APRIL, BCMA, and TACI in MM BM (supplemental Figure 6A), repeated cytotoxicity assays with ACAR-H against MM.1s at low E:T ratios (supplemental Figure 6B), and measured IFNG release (supplemental Figure 6C) in the presence of physiological levels of these proteins. There was no significant cytokine release, and ACAR-mediated target cytolysis was unaffected by soluble APRIL and soluble TACI but was reduced at the highest levels of soluble BCMA tested (P < .001 at 1000 ng/mL in comparison with media control).
Therefore in vitro, T cells transduced with both ACAR-H and ACAR-CD8 demonstrate equivalent cytolytic activity, and we consistently observed significant cytolysis of the lowest BCMA and TACI expressers even at low E:T ratios. Furthermore, ACAR killing was equivalent to that demonstrated by a scFv BCMA targeting CAR when used against BCMA-expressing targets. We also observed that ACAR T cells are not activated by soluble ligand, and though tumor kill was also unaffected by physiological levels of soluble APRIL or TACI, attenuation of target kill was seen at the highest levels of sBCMA.
APRIL CAR causes cytolysis of primary myeloma cells
To test ACAR activity on primary tumor cells, allogeneic PBMCs transduced with ACAR-H and ACAR-CD8 variants were CD56 depleted, then cocultured 1:1 with CD138-selected BM derived MM cells from 5 patients. Although BCMA and TACI expression varied between patient samples (BCMA 1224-7728 and TACI 563-1213 ABC; Figure 4A), tumor cytolysis and IFNG release were seen with both ACAR constructs in all samples. Survival and proliferation of ACAR T cells was seen with 3 patient samples (patients 23, 17, and 1 in Figure 4A).
Combining the results from the 5 patient samples, at D+3, ACAR-H and ACAR-CD8 resulted in 72.9% ± 12.2% and 87.7% ± 5.4% tumor deaths, respectively (mean ± SEM cytolysis in relation to control). In comparison, baseline tumor cell death was 2.8% ± 15.3% (P < .05 for both ACAR constructs by paired t test). There was no significant difference in target kill, cytokine release, or T-cell expansion between the 2 ACAR spacer variants (Figure 4B).
We tested the ability of ACAR constructs to induce cytolysis by TACI alone by conducting cytotoxicity assays in the presence of high concentrations of anti-BCMA monoclonal antibody (S307118G03). We observed that the antibody blocked ACAR-mediated cytolysis of U266 (BCMA+TACI−) but not MM.1s cells (BCMA+TACI+). Encouragingly, anti-BCMA antibody did not attenuate killing of primary MM cells from 3 patients who expressed both BCMA and TACI (Figure 4C).
Taken together, these experiments confirm ACAR-mediated cell death of primary MM cells and support the assumption that in the event of BCMA downregulation, tumor control could be maintained by TACI expression on primary cells.
Efficacy of APRIL CAR against myeloma in vivo
Because these in vitro assays did not show a significant difference in efficacy of ACAR-H and ACAR-CD8, we proceeded to test the smaller and thus simpler of the 2 constructs, ACAR-H in an in vivo model.
To establish an intramedullary myeloma model, we injected 22 NOD scid gamma mice intravenously with 10 × 106 HA+Fluc+MM.1s cells. Thirteen days later, there was intramedullary disease by bioluminescent imaging (BLI) in all mice (Figure 5A), at which point 5 × 106 EGFRvIII CAR or ACAR-H T cells (Figure 5B) were administered by tail vein injection into 8 animals. A single animal in the EGFRvIII CAR group did not recover following T cells, and a further mouse (with the lowest disease burden pre-CAR) had disease clearance. Nonetheless, after 2 days, there was less disease in ACAR- than in EGFRvIII CAR-treated animals by BLI (P < .01 by t test) and continued disease suppression in ACAR-treated mice (Figure 5A-B). At termination of the experiment (D+12 post-ACAR T-cells, D+25 posttumor cells), FACS of the BM confirmed significant tumor clearance in ACAR-treated animals in comparison with both control cohorts (P < .05 and P < .001 in comparison with EGFRvIII CAR and untreated cohorts; Figure 5C). Tumor clearance in the ACAR-H–treated cohort was confirmed by immunohistochemistry (Figure 5D).
Human APRIL binds murine BCMA and TACI at affinities similar to those of their human isoforms,43 and ACAR causes equivalent cytolysis of SUPT1 targets expressing human or murine BCMA and TACI (supplemental Figure 7A). This provided the unique opportunity to investigate possible off-target toxicity in our mouse xenograft model without modification to the ACAR construct. Numerous tissues were harvested from test mice (full list in the supplemental data), and on examination of formalin-fixed and paraffin-embedded, hematoxylin and eosin–stained tissue sections, we found there to be no treatment-related histopathological findings in ACAR-treated animals (supplemental Figure 7B).
Persistent disease control in an in vivo escape model
We propose dual antigen targeting as a means of reducing the risk of antigen-negative disease escape. To model the capacity for ACAR-mediated tumor control despite BCMA downregulation, we engrafted NSG mice with a mix of SUPT1BCMA and SUPT1TACI (4:1 ratio) tumor cells by tail vein before administration of ACAR or BCMA CAR.
Twenty-one NSG mice were injected with 3.5 × 106 Fluc-expressing SUPT1 cells comprising SUPT1BCMA (5807 ABC) and SUPT1TACI (2229 ABC) (80%:20%). At 4 days, mice received 5 × 106 NT T cells, ACAR, or BCMA CAR T cells (n = 7 per group) by tail vein injection. By BLI, there was continued tumor growth with NT T cells, partial disease suppression with BCMA CAR, and greatest tumor clearance in ACAR-treated animals (Figure 6A-B). On termination of the experiment (D+13 and D+9 posttumor and CAR, respectively), FACS of BM from animals receiving ACAR T cells showed clearance of both SUPT1BCMA and SUPT1TACI (P < .001 and P < .01 in comparison with NT, respectively), and BM from animals receiving BCMA CAR showed persistence of SUPT1TACI (P values nonsignificant in comparison with NT). There was continued engraftment of both tumor populations in animals receiving NT T cells (Figure 6C-D) and evident T-cell persistence in all mice (supplemental Figure 8).
These data support the assumption that in comparison with targeting BCMA alone, dual-antigen targeting of BCMA and TACI facilitates continued disease suppression in the event of BCMA downregulation or loss in patients who have tumor coexpression of both antigens.
BCMA is emerging as a lead therapeutic target in MM, as is indicated by several on-going clinical studies. The NCI group have reported 12 patients treated with their BCMA targeting CD28-CD3ζ CAR44 observing sustained responses at the highest-dose level of 9 × 106 T cells/kg24 and a further 21 patients treated with a separate (bb2121) 4-1BB-CD3ζ CAR, with consistent responses in patients administered at least 150 × 106 CAR T cells.45 Cohen et al have described their preliminary results of the first cohort treated with a 4-1BB-CD3ζ BCMA CAR.46 In this study, 3 of 9 patients developed grade 3-4 cytokine release syndrome, but notably, there were deep responses and evidence of CAR T-cell expansion without prior lymphodepleting chemotherapy. Alternative T-cell redirecting therapies are CD3-BCMA bispecific molecules on a common IgG arm,47,48 or bispecific T-cell engagers, in which scFvs to CD3 and BCMA are joined by a small peptide linker.23,49 Additionally, a phase I study of an antibody-drug conjugate utilizing the antitubulin agent, monomethyl auristatin F, reported an overall response rate of 67% in their high-dose groups in multiply relapsed patients.50
Although these BCMA-targeted therapies show promise, this receptor is present on tumor cells at variable and often low levels.16,17 We found the median surface BCMA expression on MM cells to be over a log less than CD19 on acute lymphoblastic leukemia (ALL).6 Moreover, antigen-negative tumor escape is well described in B-cell malignancies, with an incidence exceeding 10% in patients with ALL treated with a CD19 CAR.6,25 In the BCMA CAR study described by the University of Pennsylvania group,46 disease progression in 2 patients was associated with reduction in BCMA expression, reminiscent of the report from the NCI group using their first BCMA CAR.24 These observations prompt a re-evaluation of such therapies targeting a single antigen.
We found BCMA and TACI to be coexpressed on the tumor for the majority (78%) of patients, and we hypothesized that targeting 2 tumor antigens could overcome the challenges of low target levels and antigen escape when targeting BCMA alone. To date, there have been several approaches to creating dual-targeting CARs. These strategies have included the admixing of 2 populations of CAR-transduced T cells,51 engineering a single CAR construct containing 2 separate scFvs in tandem (TanCAR)52,53 or the coexpression of 2 CARs on T cells using a bicistronic vector or double transduction (OR gate).54,55 In the context of low levels of target antigen, the first approach may not ensure maximal T-cell activation, because only BCMA or TACI would be recognized by individual T cells. A bivalent TanCAR may result in lower numbers of ligated receptors per target cell in target-limited conditions; finally, an OR gate requires a large, complex bicistronic vector or a complex double transduction.
In comparison, APRIL is compact (135aa), nonimmunogenic, and natively bispecific, binding either MM antigen31 with high affinity. Using APRIL as the CAR binder, we report target cytolysis at low E:T ratios that enforce an assessment of serial kill and at low levels of target antigen, such as are present on primary tumor cells. ACAR-mediated cytolysis was also achieved at low levels of TACI, when BCMA targeting was blocked, thus indicating the possibility of ACAR-mediated disease control, even with BCMA downregulation or loss. Data exist that demonstrate resistance of CARs to blocking by avidity effects,56,57 and we observed reduction in ACAR killing at the highest levels of sBCMA found in MM BM but not with physiological concentrations of APRIL or TACI. In confirmation of our in vitro findings, we observed tumor regression of established disease after only 48 hours of ACAR T-cell infusion in an intramedullary murine myeloma model. Notably, using an in vivo model of tumor escape, we observed improved disease control in comparison with a CAR targeting BCMA alone.
BCMA and TACI are both lymphoid antigens. BCMA is vital for the survival of long-lived PC,58 is upregulated in late-memory B cells on committing to the PC lineage,59,60 and is thus present on normal and malignant PC.16,17 In comparison, TACI expression is found primarily on maturing B cells, particularly marginal-zone B cells, CD27+ memory B-cell subsets and PC.37,59 Our qRT-PCR analysis of TACI transcripts indicates expression restricted to the lymphoid compartments. Furthermore, ACAR does not appear to result in tissue toxicity in an animal model. We expect that ACAR therapy would result in loss of the entire plasma cell compartment and a subset of the B-cell compartment. The subsequent hypogammaglobinaemia may be more profound than that of CD19 targeting61 but should not be more severe than that of BCMA targeting alone.
TACI has been implicated as both a positive and a negative immune regulator,62-65 and gene disruptions are found in 8% of patients with common variable immunodeficiency.27,63 TACI also drives PC differentiation,66 suggesting that TACI is expressed early in PC development. We describe tumor TACI expression in the majority of patients and, given the ontogeny of TACI expression, speculate that in these patients at least, expression of this antigen on putative myeloma stem cells that have a role in disease relapse and drug resistance67,68 would add a further advantage to this approach.
In summary, using a novel ligand-based approach, we have demonstrated that the ACAR can concurrently target BCMA and TACI to increase the number of targetable tumor antigens in the majority of MM patients. ACAR T cells were able to kill targets expressing either receptor, and significant killing was seen at physiological receptor levels, at low E:T ratios, or with BCMA blockade. ACAR T cells also killed primary myeloma cells in vitro, and we observed rapid and complete tumor clearance in vivo in comparison with an irrelevant CAR, as well as in our tumor escape model in comparison with a CAR targeting BCMA alone. These observations suggest that dual-antigen targeting of BCMA and TACI by ACAR T cells may improve on the initial clinical responses seen with BCMA targeting CARs, both by extending clinical applicability to those patients with low levels of tumor BCMA and by reducing the risk of antigen-negative escape.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
This work was supported by grants from Bloodwise (12062) (L.L.) and the Kay Kendall Leukaemia Fund (KKL726) (N.C., B.D.). The work was undertaken at University College London/University College London Hospitals, which is an National Institute for Health Research Biomedical Research Centre, a Cancer Research UK Cancer Centre, and a Bloodwise Research Centre of Excellence.
Contribution: M.P. conceived the project; L.L., K.Y., and M.P. designed the study; S.O., M.R.-J., K.Y., and M.P. supervised the work; L.L., B.D., N.C., B.P., M.C., D.G.-F., S.O., S.T., V.B., R.B., P.M., E.K., M.P.N., and D.P. performed the work; L.L., S.O., and J.F. analyzed the data; L.L. wrote the paper; and J.F., K.Y., and M.P. reviewed the paper.
Conflict-of-interest disclosure: L.L. received funding from Bloodwise Research. K.Y. received funding from Janssen Research. L.L., B.D., N.C., P.M., K.Y., and M.P. own equity in Autolus. L.L., B.D., N.C., K.Y., and M.P. own the patent for APRIL CAR. S.O., S.T., V.B., R.B., E.K., J.F., and M.P. are employees of Autolus. M.P. has received honoraria from Amgen and Roche. The remaining authors declare no competing financial interests.
Correspondence: Lydia Lee, University College London Cancer Institute, Department of Haematology, 72 Huntley St, London, WC1E 6DD, United Kingdom; e-mail: email@example.com.
K.Y. and M.P. contributed equally to this study.